Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Aptamer Group

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows...

Verici Dx: Tutivia Set to Disrupt Transplant Monitoring with Real-Time RNA Insights (Video)

Tutivia is turning heads in transplant care. Verici Dx CEO Sara Barrington explains how their RNA-based rejection test is setting new standards in real-world use—and why clinicians and payers are getting on board...
AstraZeneca

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial execution and pipeline progress...
GSK

GSK receives EU approval for Nucala in Eosinophilic COPD

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils...
Brava Health

Brava Health CMO urges human-centred approach to MedTech

Brava Health’s CMO calls on the MedTech industry to align innovation with clinical responsibility at a key industry event...
Verici Dx Plc

Verici Dx delivers FY25 growth as Tutivia™ commercialisation accelerates

For the year ended 31 December 2025, Verici Dx Plc reported unaudited revenues of $3.8m, driven by first recognised Tutivia™ revenues, increased test volumes, and expanded US reimbursement coverage...
Verici Dx

Verici Dx secures BCBS Illinois agreement for Tutivia kidney transplant test

Verici Dx Plc has entered into an agreement with Blue Cross and Blue Shield of Illinois to provide in-network coverage for Tutivia™, its post-kidney transplant diagnostic test...
Oxford Biomedica Plc

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes...
GSK

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV...
Cizzle Bio

Cizzle Biotechnology secures Canadian patent for CIZ1B lung cancer test

Cizzle Biotechnology has been granted Canadian patent protection for methods measuring the CIZ1B lung cancer biomarker, strengthening its intellectual property portfolio...
AstraZeneca

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure...
Brava Health

Delay damages patients, and the system pays for it

In joint surgery, delays don’t just postpone care, they increase risk, reduce recovery and raise long-term cost...
AstraZeneca

AstraZeneca signs $1.2bn obesity drug collaboration with CSPC

Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I...
Aptamer Group

Aptamer Group secures £270k in new orders and first cash licensing receipts

Aptamer Group plc has announced £190,000 in new fee-for-service Optimer® orders and £80,000 in cash licensing receipts, including its first payment from a hot-start PCR licence...
Physicians Capital

Positioning physician practices for long-term financial control

Earl Anderson shares how physician practices are adapting strategy and ownership to stay financially viable in a changing healthcare market...
Verici Dx Plc

Tutivia™ study confirms predictive value in transplant care

AI-powered kidney transplant test flags risk of rejection before symptoms appear, study shows...
Brava Health

Brava Health builds infrastructure for individual-led healthcare

Brava Health is making health data user-owned and ready for the future of care...
GSK

EU approves GSK’s Arexvy RSV vaccine for adults 18+

GSK plc announced that the European Commission has approved its RSV vaccine, Arexvy, for use in adults aged 18 years and older...
Ethtry plc

Ethtry Plc publishes new Company Presentation

Ethtry has published a new Company presentation outlining its strategy, business model, and growth outlook across key markets, including tokenised assets and sovereign blockchain infrastructure...
Physicians Capital

Who owns healthcare now?

Invest in the platforms, that’s where healthcare value lives now...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Aptamer Group

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows...

Verici Dx: Tutivia Set to Disrupt Transplant Monitoring with Real-Time RNA Insights (Video)

Tutivia is turning heads in transplant care. Verici Dx CEO Sara Barrington explains how their RNA-based rejection test is setting new standards in real-world use—and why clinicians and payers are getting on board...
AstraZeneca

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial execution and pipeline progress...
GSK

GSK receives EU approval for Nucala in Eosinophilic COPD

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils...
Brava Health

Brava Health CMO urges human-centred approach to MedTech

Brava Health’s CMO calls on the MedTech industry to align innovation with clinical responsibility at a key industry event...
Verici Dx Plc

Verici Dx delivers FY25 growth as Tutivia™ commercialisation accelerates

For the year ended 31 December 2025, Verici Dx Plc reported unaudited revenues of $3.8m, driven by first recognised Tutivia™ revenues, increased test volumes, and expanded US reimbursement coverage...
Verici Dx

Verici Dx secures BCBS Illinois agreement for Tutivia kidney transplant test

Verici Dx Plc has entered into an agreement with Blue Cross and Blue Shield of Illinois to provide in-network coverage for Tutivia™, its post-kidney transplant diagnostic test...
Oxford Biomedica Plc

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes...
GSK

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV...
Cizzle Bio

Cizzle Biotechnology secures Canadian patent for CIZ1B lung cancer test

Cizzle Biotechnology has been granted Canadian patent protection for methods measuring the CIZ1B lung cancer biomarker, strengthening its intellectual property portfolio...
AstraZeneca

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure...
Brava Health

Delay damages patients, and the system pays for it

In joint surgery, delays don’t just postpone care, they increase risk, reduce recovery and raise long-term cost...
AstraZeneca

AstraZeneca signs $1.2bn obesity drug collaboration with CSPC

Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I...
Aptamer Group

Aptamer Group secures £270k in new orders and first cash licensing receipts

Aptamer Group plc has announced £190,000 in new fee-for-service Optimer® orders and £80,000 in cash licensing receipts, including its first payment from a hot-start PCR licence...
Physicians Capital

Positioning physician practices for long-term financial control

Earl Anderson shares how physician practices are adapting strategy and ownership to stay financially viable in a changing healthcare market...
Verici Dx Plc

Tutivia™ study confirms predictive value in transplant care

AI-powered kidney transplant test flags risk of rejection before symptoms appear, study shows...
Brava Health

Brava Health builds infrastructure for individual-led healthcare

Brava Health is making health data user-owned and ready for the future of care...
GSK

EU approves GSK’s Arexvy RSV vaccine for adults 18+

GSK plc announced that the European Commission has approved its RSV vaccine, Arexvy, for use in adults aged 18 years and older...
Ethtry plc

Ethtry Plc publishes new Company Presentation

Ethtry has published a new Company presentation outlining its strategy, business model, and growth outlook across key markets, including tokenised assets and sovereign blockchain infrastructure...
Physicians Capital

Who owns healthcare now?

Invest in the platforms, that’s where healthcare value lives now...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple